Found 386 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas
This study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection surgery. Potential patients who sign informed consent will be screened for eligibility before receiving an oral solution of Gleolan 3 hours prior to …
Combination Ipatasertib and Atezolizumab to Prevent Recurrence in Triple Negative Breast Cancer
The purpose of this study is to determine if a combination of two drugs, Ipatasertib and Atezolizumab, works as a treatment for residual cancer in breast or lymph nodes and have circulating tumor DNA in blood. Eligible subjects will be those with triple negative breast cancer.
UPCC 24116: A Phase II Pilot Trial of Hydroxychloroquine Everolimus or the Combination for Prevention of Recurrent Breast Cancer
The main purpose of this study is to: 1) determine the feasibility of giving hydroxychloroquine, everolimus or the combination to people with disseminated tumor cells detected in their bone marrow. 2) determine how tolerable these drugs are in people who have completed treatment for breast cancer. 3) determine how well …
UPCC 10122 A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Endometrial Cancer Molecularly Targeted Therapy Consortium
The purpose of this study is to confirm that tumor alterations and biomarkers can direct biologic therapies and potentially enhance survival outcomes in women with Endometrial Cancer
UPCC 04223: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
UPCC 28921: A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumours
This study has a mono therapy arm and a combination therapy arm. The main purpose of the mono therapy arm is to test the safety and tolerability of ART4215 in humans. The main purpose of the combination therapy arm is to test ART4215 compared to and in combination with talazoparib.
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, andAnti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected SolidTumors
To evaluate an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors. A personalized vaccine, consisting of between 4 to 20 synthetic long peptides, will be generated for each patient and shall be administered as an adjuvanted vaccine, with the adjuvant Hiltonol.
Study of lurbinectedin efficacy and safety in participants with advanced or metastatic solid tumors
This research study is designed to learn more about the safety and effectiveness of lurbinectedin given to individuals who have been diagnosed with advanced (metastatic and/or unresectable) solid tumors.
Please choose between Voice or SMS based delivery of verification code
or